CF
ATNM icon

Corebridge Financial’s Actinium Pharmaceuticals ATNM Stock Holding History

Corebridge Financial’s Portfolio ATNM Stock Details ATNM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-15,406
Closed -$24.8K – 251
2025
Q1 		$24.8K Sell
15,406
-229
-1% -$291 ﹤0.01% 2873
2024
Q4 		$19.7K Sell
15,635
-440
-3% -$683 ﹤0.01% 2965
2024
Q3 		$30.2K Sell
16,075
-99
-0.6% -$391 ﹤0.01% 2949
2024
Q2 		$120K Buy
+16,174
New +$133K ﹤0.01% 2490

Other funds holding ATNM

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
GS
Gagnon Securities New York $433M AUM 29.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
CFD
Creative Financial Designs Kokomo, Indiana $1.65B AUM 15.6% 1-Year Est. Return

Corebridge Financial's ATNM Position: Q2 2025 in Review

Corebridge Financial sold out of Actinium Pharmaceuticals (ATNM) in Q2 2025, closing a stake of 15,406 shares — an estimated $24.8K sold.

Corebridge Financial first reported a position in ATNM in Q2 2024 and held it in 4 quarters. The position peaked at $120K in Q2 2024. 63 funds tracked by Wall St. Rank hold ATNM as of Q2 2025.

  • Corebridge Financial reported no remaining Actinium Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Corebridge Financial sold 15,406 Actinium Pharmaceuticals shares in Q2 2025, an estimated $24.8K.
  • Corebridge Financial first reported a position in Actinium Pharmaceuticals in Q2 2024 and held it in 4 quarters.
  • Corebridge Financial's Actinium Pharmaceuticals position peaked at $120K in Q2 2024.
  • 63 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q2 2025.

Based on Corebridge Financial's 13F filing for Q2 2025, filed 12 Aug 2025.